<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00447759</url>
  </required_header>
  <id_info>
    <org_study_id>SCOT Trial</org_study_id>
    <nct_id>NCT00447759</nct_id>
  </id_info>
  <brief_title>The Standard Care Versus Celecoxib Outcome Trial</brief_title>
  <acronym>SCOTLSSS</acronym>
  <official_title>Phase 4 Study A Large Streamline Safety Study Designed to Compare the Cardiovascular Safety od Celecoxib Versus Traditional Non-selective NSAID's</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Dundee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Glasgow</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Nottingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Dundee</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Standard Care versus Celecoxib Outcome Trial (SCOT) is a large streamline safety study
      designed to compare the cardiovascular safety of celecoxib versus traditional non-selective
      Non Steroidal Anti-Inflammatory Drug (NSAID) therapy.Traditional NSAID's are associated with
      significant morbidity and mortality from gastrointestinal toxicity. Cyclooxygenase 2
      (Cox-2)selective agents are associated with reduced upper gastrointestinal
      toxicity.Traditional NSAID's and Cox-2 inhibitors may also be associated with cardiovascular
      and renal disorders. Data from both randomised and observational studies suggest that
      celecoxib has similar or reduced cardiovascular toxicity when compared to traditional
      NSAID's. However, the overall safety balance of a strategy of celecoxib therapy versus a
      strategy of NSAID therapy is unknown. The European Medicines Evaluation Agency (EMEA) has
      requested that studies of the cardiovascular safety of celecoxib be carried out within the
      indicated population of Europe. This study addresses these issues by comparing the
      cardiovascular safety of celecoxib therapy with traditional NSAID therapy in the setting of
      the EU healthcare system.

      As of May 2013, 7300 patients had been randomised, and had accrued an average 4.2 years of
      follow up by the end of May 2014.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aims

      The present proposal seeks to compare the cardiovascular and gastrointestinal safety and
      effectiveness of a strategy of initial randomisation to treatment with the selective COX-2
      inhibitor celecoxib or to 'usual-care' with their current non-selective NSAID therapy (with
      or without cyto-protection with ulcer healing drug use in either celecoxib or 'usual-care'
      limbs).

      Trial Design

      This trial utilises the Prospective Randomised Open Blinded End point (PROBE) design .
      Patients with clinically diagnosed osteoarthritis (OA) or rheumatoid arthritis (RA) 60 years
      of age or more who are free from established cardiovascular disease and who require chronic
      NSAID therapy will be identified in the setting of primary care. Patients will be randomised
      to receive either celecoxib or to continue their previous standard NSAID therapy. They will
      then be followed up for an average of 4.2 years in the setting of the local National
      Healthcare system. The study will terminate when 277 adjudicated cardiovascular events have
      accrued. A summary is shown in the diagram below.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare cardiovascular safety of celecoxib and traditional NSAIDs prescribed for the treatment of arthritis.</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Is to demonstrate the superiority of celecoxib over traditional NSAIDs on ulcer-related upper gastrointestinal complications.</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7300</enrollment>
  <condition>Osteoarthritis</condition>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Celecoxib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NSAID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>200-400mg daily in divided doses</description>
    <arm_group_label>Celecoxib</arm_group_label>
    <other_name>Celebrex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>non-selective Non steroidal anti inflammatory Drug</intervention_name>
    <description>taken orally</description>
    <arm_group_label>NSAID</arm_group_label>
    <other_name>Diclofenac</other_name>
    <other_name>Ibuprofen</other_name>
    <other_name>Naproxen</other_name>
    <other_name>meloxicam</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects 60 years or over Male &amp; Female

          -  Chronic NSAIDs use for 90 days or more in a 12 month period

          -  Subjects who have a licensed indication for chronic non-selective NSAID or Celecoxib.

          -  Eligible for treatment with either Celecoxib or alternative traditional non-selective
             NSAID.

          -  Subjects who are willing to consent to their paper and electronic medical records and
             prescribing data to be accessed.

          -  Subjects who are willing to be contacted and interviewed by trial investigators.

        Exclusion Criteria:

          -  Established cardiovascular disease including ischaemic heart disease, Myocardial
             Infarction, angina or acute coronary syndrome, cerebrovascular disease or
             cerebrovascular accident or transient ischaemic attack, established peripheral
             vascular disease and moderate to severe heart failure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas M MacDonald, MD MRCP FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Dundee</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ian Ford, FRCP FRSE</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Glasgow</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christopher J Hawkey, MRCP DM FRC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nottingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Southern Denmark</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Julius Clinical Research</name>
      <address>
        <city>Zeist</city>
        <zip>3703 CD Zeist</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Aberdeen</name>
      <address>
        <city>Aberdeen</city>
        <zip>AB25 2ZN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Birmingham</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Dundee</name>
      <address>
        <city>Dundee</city>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Glasgow</name>
      <address>
        <city>Glasgow</city>
        <zip>G11 6NT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHS Highlands</name>
      <address>
        <city>Inverness</city>
        <zip>IV2 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nottingham</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oxford</name>
      <address>
        <city>Oxford</city>
        <zip>OX1 2ET</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.scottrial.co.uk/</url>
    <description>SCOT study website</description>
  </link>
  <link>
    <url>http://www.dundee.ac.uk/memo/</url>
    <description>MEMO website</description>
  </link>
  <reference>
    <citation>MacDonald TM. A European's perspective of COX-2 drug safety. J Cardiovasc Pharmacol. 2006;47 Suppl 1:S92-7.</citation>
    <PMID>16785838</PMID>
  </reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2007</study_first_submitted>
  <study_first_submitted_qc>March 14, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2007</study_first_posted>
  <last_update_submitted>January 7, 2016</last_update_submitted>
  <last_update_submitted_qc>January 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Dundee</investigator_affiliation>
    <investigator_full_name>Thomas M MacDonald</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Celecoxib</keyword>
  <keyword>Celebrex</keyword>
  <keyword>Ibuprofen</keyword>
  <keyword>Diclofenac</keyword>
  <keyword>NSAID</keyword>
  <keyword>Osteoarthritis</keyword>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Arthritis</keyword>
  <keyword>Safety study</keyword>
  <keyword>Cardiovascular safety</keyword>
  <keyword>Clinical trial</keyword>
  <keyword>PROBE design</keyword>
  <keyword>University of Dundee</keyword>
  <keyword>Medicines Monitoring Unit</keyword>
  <keyword>MEMO</keyword>
  <keyword>Professor Tom MacDonald</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Diclofenac</mesh_term>
    <mesh_term>Anti-Inflammatory Agents, Non-Steroidal</mesh_term>
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>May 8, 2017</submitted>
    <returned>October 10, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

